Understanding Glioblastoma: The Aggressive Brain Cancer Professor Richard Scolyer Fought
Professor Richard Scolyer, a pioneering Australian researcher, dedicated the final years of his life to the formidable challenge of finding a cure for glioblastoma, an aggressive form of brain cancer. Tragically, this relentless disease ultimately claimed his life. Diagnosed in 2023, Professor Scolyer bravely opted to bypass conventional treatments, instead participating in a world-first experimental immunotherapy trial. This bold decision allowed him to live significantly longer than his initial prognosis suggested. Despite his personal breakthrough and the knowledge gained, glioblastoma remains one of the most challenging cancers to treat globally.
What Exactly is Glioblastoma?
Glioblastoma is recognised as the most aggressive form of brain cancer. It is classified as a Grade 4 tumour, the most severe category assigned to brain cancers. Each year, approximately 2,000 Australians are diagnosed with brain cancer, with a significant portion, around 1,000 to 1,200 of these cases, being glioblastoma.
Dr Stephen Lewis, a neurosurgeon at Perth Neurosurgery, explains that these tumours originate from astrocytes, which are cells crucial for supporting and protecting the brain. “Unlike many other cancers, glioblastoma tends to grow by sending microscopic tumour cells deep into the surrounding brain tissue. This makes it extremely difficult to remove completely,” Dr Lewis stated.
While glioblastoma can affect individuals at any age, it is most commonly diagnosed in people between the ages of 55 and 75. The average life expectancy for patients diagnosed with this condition is a stark 15 to 18 months. Professor Pieter Eichhorn from Curtin University’s medical school notes that “Only 25 per cent of patients survive beyond two years.”
Recognising the Symptoms of Glioblastoma
The symptoms of glioblastoma can be varied, depending on the specific location of the tumour within the brain and which brain regions are affected. Professor Anna Nowak, a clinical academic medical oncologist and Deputy Vice Chancellor (Research) at the University of Western Australia, highlights that the initial signs can often be mistaken for other serious medical emergencies. “First symptoms can be similar to symptoms of a stroke,” she advised.
Common warning signs that may indicate the presence of glioblastoma include:
- Seizures
- Persistent headaches
- Nausea and vomiting
- Difficulties with speech
- Weakness affecting one side of the body
- Changes in vision
- Confusion
- Alterations in personality
The Elusive Search for a Cure
Despite significant advancements in cancer treatment over the past few decades, a definitive cure for glioblastoma remains elusive. The current standard treatment protocol typically involves:
- Surgery: The primary goal of surgery is to remove as much of the tumour as possible.
- Radiotherapy and Chemotherapy: These treatments are often delivered concurrently for a period of up to six weeks.
- Adjuvant Chemotherapy: Following the initial intensive treatment, patients usually continue with further chemotherapy, often in the form of oral tablets.
Additionally, doctors may prescribe medications to help manage seizures and reduce swelling in the brain. Professor Eichhorn pointed out the limitations of current approaches, stating, “Unfortunately, these treatments are the same ones that we have been using for the last 20 to 25 years.”
Glioblastoma has a high tendency to recur or progress even after treatment. In such instances, patients may be offered additional therapies or the opportunity to participate in clinical trials, provided their general health permits. Immunotherapy, a treatment approach that Professor Scolyer had pioneered for melanoma and later trialled on himself for glioblastoma, is still considered experimental for this specific brain cancer and is an active area of investigation in ongoing clinical trials.
Why is Glioblastoma So Difficult to Treat?
The inherent nature of glioblastoma presents significant challenges for medical professionals. One of the most substantial hurdles is the inability of surgeons to completely remove the tumour without risking severe damage to the brain. Professor Nowak elaborated on this, explaining that the tumour’s infiltrative growth pattern makes complete excision impossible. “The brain is such a critical organ that surgeons can only remove the main bulk of the glioblastoma, and there is always cancer left behind because it tends to infiltrate into other important adjacent areas of the brain,” she said.
Unlike cancers in other parts of the body, surgeons cannot safely remove a wide margin of healthy tissue surrounding a brain tumour. Doing so could lead to permanent impairment of vital functions such as speech, motor control, or cognitive abilities. Professor Eichhorn vividly described the spread of glioblastoma as being “like a spider web, with microscopic thread-like cancer cells spreading everywhere.”
Furthermore, researchers have struggled to identify a specific molecular target that can be effectively blocked with drug therapies, a strategy that has proven successful for many other types of cancer. Glioblastoma also exhibits a high degree of resistance to treatment, meaning that even established therapies may yield limited success in some individuals.
The Pivotal Role of Professor Richard Scolyer’s Case
Professor Richard Scolyer’s personal battle with glioblastoma garnered global attention. He made the courageous decision to forgo standard glioblastoma treatment in favour of an experimental approach, drawing upon his extensive research in melanoma. Collaborating with his colleague, Professor Georgina Long, he became the first brain cancer patient worldwide to receive combination immunotherapy prior to surgery. Subsequently, he underwent treatment with a personalised anti-cancer vaccine, designed to empower his immune system to detect and attack tumour cells.
For an impressive period of nearly eighteen months, Professor Scolyer’s regular scans showed no signs of tumour recurrence. However, the cancer re-emerged in early 2025, necessitating further brain surgery after doctors identified a larger, rapidly progressing tumour. At the time, Professor Scolyer acknowledged the grim reality, stating, “The prognosis is poor.”
While his personal fight did not result in a cure, the scientific insights and data gathered from Professor Scolyer’s unique case are considered invaluable. Researchers are hopeful that the knowledge gained will significantly contribute to future efforts aimed at combating this devastating disease.
